LAEKNA-B (02105) Surges Nearly 5% in Afternoon Trading as US FDA Accepts LAE118 New Drug Clinical Trial Application

Stock News01-16

LAEKNA-B (02105) rose nearly 5% during the afternoon session. At the time of writing, the stock was up 3.04%, trading at HK$13.88, with a turnover of HK$19.92 million.

The company announced that the US Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for LAE118, a new drug with the potential to treat solid tumors with PIK3CA mutations, such as breast cancer.

LAE118 is described as a novel, pan-mutant selective PI3Kα inhibitor, representing a new therapeutic approach for PIK3CA-mutated solid tumors.

The announcement stated that the company will work closely with regulatory authorities to complete the relevant application.

Leveraging its strong and proven track record in clinical development and the out-licensing of LAE002 (afuresertib), the company is committed to providing this precise treatment for cancer patients in need of novel therapeutic options.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179784108?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 13:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179784108","market":"sg","top_or_hot":-1,"title":"LAEKNA-B (02105) Surges Nearly 5% in Afternoon Trading as US FDA Accepts LAE118 New Drug Clinical Trial Application","media":"Stock News","content":"<p>LAEKNA-B (02105) rose nearly 5% during the afternoon session. At the time of writing, the stock was up 3.04%, trading at HK$13.88, with a turnover of HK$19.92 million.</p>\n<p>The company announced that the US Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for LAE118, a new drug with the potential to treat solid tumors with PIK3CA mutations, such as breast cancer.</p>\n<p>LAE118 is described as a novel, pan-mutant selective PI3Kα inhibitor, representing a new therapeutic approach for PIK3CA-mutated solid tumors.</p>\n<p>The announcement stated that the company will work closely with regulatory authorities to complete the relevant application.</p>\n<p>Leveraging its strong and proven track record in clinical development and the out-licensing of LAE002 (afuresertib), the company is committed to providing this precise treatment for cancer patients in need of novel therapeutic options.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LAEKNA-B (02105) Surges Nearly 5% in Afternoon Trading as US FDA Accepts LAE118 New Drug Clinical Trial Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLAEKNA-B (02105) Surges Nearly 5% in Afternoon Trading as US FDA Accepts LAE118 New Drug Clinical Trial Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-16 13:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LAEKNA-B (02105) rose nearly 5% during the afternoon session. At the time of writing, the stock was up 3.04%, trading at HK$13.88, with a turnover of HK$19.92 million.</p>\n<p>The company announced that the US Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for LAE118, a new drug with the potential to treat solid tumors with PIK3CA mutations, such as breast cancer.</p>\n<p>LAE118 is described as a novel, pan-mutant selective PI3Kα inhibitor, representing a new therapeutic approach for PIK3CA-mutated solid tumors.</p>\n<p>The announcement stated that the company will work closely with regulatory authorities to complete the relevant application.</p>\n<p>Leveraging its strong and proven track record in clinical development and the out-licensing of LAE002 (afuresertib), the company is committed to providing this precise treatment for cancer patients in need of novel therapeutic options.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02105","symbol_name":"来凯医药-B","start_time":0,"source_url":"","article_id":"1179784108","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179784108","pubTimestamp":1768542288,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LAEKNA-B (02105) rose nearly 5% during the afternoon session. At the time of writing, the stock was up 3.04%, trading at HK$13.88, with a turnover of HK$19.92 million. The company announced that the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02105":"来凯医药-B","BK1161":"生物科技"},"translate_title":"LAEKNA-B(02105)午盘大涨近5%，因美国FDA受理LAE118新药临床试验申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":1},"content_text":"LAEKNA-B (02105) rose nearly 5% during the afternoon session. At the time of writing, the stock was up 3.04%, trading at HK$13.88, with a turnover of HK$19.92 million.\nThe company announced that the US Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for LAE118, a new drug with the potential to treat solid tumors with PIK3CA mutations, such as breast cancer.\nLAE118 is described as a novel, pan-mutant selective PI3Kα inhibitor, representing a new therapeutic approach for PIK3CA-mutated solid tumors.\nThe announcement stated that the company will work closely with regulatory authorities to complete the relevant application.\nLeveraging its strong and proven track record in clinical development and the out-licensing of LAE002 (afuresertib), the company is committed to providing this precise treatment for cancer patients in need of novel therapeutic options.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179784108","isCrawlerRequest":true}